NASDAQ:HRTX - Heron Therapeutics Stock Price, Price Target & More

$31.15 +1.30 (+4.36 %)
(As of 04/22/2018 06:48 AM ET)
Previous Close$31.15
Today's Range$29.85 - $31.35
52-Week Range$12.70 - $32.70
Volume1.06 million shs
Average Volume1.31 million shs
Market Capitalization$2.20 billion
P/E Ratio8.53
Dividend YieldN/A
Beta1.88

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics logoHeron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio2.21%
Quick Ratio2.11%

Price-To-Earnings

Trailing P/E Ratio8.53
Forward P/E Ratio-12.56
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.77 million
Price / Sales71.48
Cash Flow$3.0872 per share
Price / Cash10.09
Book Value$2.03 per share
Price / Book15.34

Profitability

EPS (Most Recent Fiscal Year)$3.65
Net Income$-197,480,000.00
Net Margins-641.87%
Return on Equity-230.70%
Return on Assets-115.42%

Miscellaneous

Employees145
Outstanding Shares70,610,000

How to Become a New Pot Stock Millionaire

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics (NASDAQ:HRTX) posted its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.30. The biotechnology company had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9 million. Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. View Heron Therapeutics' Earnings History.

What price target have analysts set for HRTX?

12 analysts have issued twelve-month price targets for Heron Therapeutics' stock. Their forecasts range from $22.00 to $56.00. On average, they expect Heron Therapeutics' stock price to reach $37.4167 in the next year. View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. Cowen Inc analysts commented, "We are still waiting to speak with the company and have thus not yet updated our model and price target, but do not recommend buying on weakness." (3/19/2018)
  • 2. Mizuho analysts commented, "We believe the results demonstrate the superior product profile of HTX-011 in post-operative pain management compared to the current standard of care. We raise our PT from $28 to $35." (3/19/2018)
  • 3. Cantor Fitzgerald analysts commented, "Late Friday, Jan. 12, Tesaro (Not Covered) announced that it had modified the Warnings section of the package insert for Varubi to include post-marketing reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions, some requiring hospitalization." (1/15/2018)
  • 4. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/10/2018)

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:
  • Dr. Barry D. Quart, Chief Exec. Officer and Director (Age 61)
  • Mr. Robert H. Rosen, Pres and Director (Age 62)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 58)
  • Mr. Robert E. Hoffman, Chief Financial Officer and Sr. VP of Fin. (Age 52)
  • Mr. David L. Szekeres, Sr. VP - Bus. Devel., Gen. Counsel & Corp. Sec. (Age 44)

Has Heron Therapeutics been receiving favorable news coverage?

Headlines about HRTX stock have trended positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Heron Therapeutics earned a news sentiment score of 0.44 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.71 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $31.15.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $2.20 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or $3.65 on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]


MarketBeat Community Rating for Heron Therapeutics (HRTX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  406 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  580
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Heron Therapeutics (NASDAQ:HRTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Heron Therapeutics in the last 12 months. Their average twelve-month price target is $37.4167, suggesting that the stock has a possible upside of 20.12%. The high price target for HRTX is $56.00 and the low price target for HRTX is $22.00. There are currently 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $37.4167$34.3636$29.90$30.1111
Price Target Upside: 20.12% upside25.64% upside38.43% upside94.27% upside

Heron Therapeutics (NASDAQ:HRTX) Consensus Price Target History

Price Target History for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2018Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
4/5/2018Evercore ISIInitiated CoverageOutperform$56.00MediumView Rating Details
4/5/2018Lake Street CapitalSet Price TargetBuy$42.00MediumView Rating Details
3/27/2018OppenheimerSet Price TargetBuy$34.00LowView Rating Details
3/26/2018Northland SecuritiesReiterated RatingBuy$55.00LowView Rating Details
3/21/2018Noble FinancialReiterated RatingBuyLowView Rating Details
3/20/2018Needham & Company LLCBoost Price TargetBuy$42.00MediumView Rating Details
3/19/2018CowenReiterated RatingBuyMediumView Rating Details
3/19/2018MizuhoReiterated RatingBuy -> Buy$28.00 -> $35.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$22.00HighView Rating Details
8/16/2017Jefferies GroupReiterated RatingBuyLowView Rating Details
7/18/2017AegisReiterated RatingBuy$33.00LowView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Heron Therapeutics (NASDAQ:HRTX) Earnings History and Estimates Chart

Earnings by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.86)($0.69)($0.75)
Q2 20183($0.70)($0.64)($0.66)
Q3 20183($0.69)($0.36)($0.53)
Q4 20183($0.71)($0.25)($0.45)

Heron Therapeutics (NASDAQ HRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018Q4 2017($0.7950)($1.09)$9.00 million$10.05 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.87)($0.77)$8.12 million$8.57 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.8990)($0.80)$4.53 million$8.51 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.9380)($1.00)$1.96 million$3.63 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.17)($1.22)$1.07 million$1.28 millionViewN/AView Earnings Details
11/8/2016Q3 2016($1.17)($1.24)ViewN/AView Earnings Details
8/8/2016Q2($0.96)($1.17)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.6370)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.64)($0.70)ViewN/AView Earnings Details
3/13/2015Q4 2014($0.69)($0.71)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014Q2 2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.58)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.80)($0.80)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.80)($1.00)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.60)($0.80)ViewN/AView Earnings Details
3/1/2013Q4 2012($0.40)($0.60)ViewN/AView Earnings Details
11/5/2012Q3 2012($0.20)($0.40)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.40)($0.40)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.40)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.42)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.94)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.66)ViewN/AView Earnings Details
3/28/2011Q4 2010($0.76)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.82)ViewN/AView Earnings Details
8/16/2010Q2 2010($1.88)ViewN/AView Earnings Details
5/17/2010Q1 2010($1.46)ViewN/AView Earnings Details
3/15/2010Q4 2009($1.22)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.80)ViewN/AView Earnings Details
8/4/2009Q2 2009($2.54)ViewN/AView Earnings Details
5/14/2009Q1 2009($2.00)($1.92)ViewN/AView Earnings Details
3/31/2009Q4 2008($4.00)($2.50)ViewN/AView Earnings Details
11/5/2008Q3 2008($4.40)($4.02)ViewN/AView Earnings Details
8/14/2008Q2 2008($3.98)ViewN/AView Earnings Details
5/15/2008Q1 2008($4.44)ViewN/AView Earnings Details
3/13/2008Q4 2007($3.80)($5.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Heron Therapeutics (NASDAQ:HRTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Heron Therapeutics (NASDAQ HRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.93%
Institutional Ownership Percentage: 97.41%
Insider Trading History for Heron Therapeutics (NASDAQ:HRTX)
Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ HRTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Kevin C TangDirectorBuy192,308$26.00$5,000,008.00View SEC Filing  
3/19/2018Barry D QuartCEOSell100,000$29.75$2,975,000.00167,993View SEC Filing  
3/19/2018Kimberly ManhardVPSell18,000$30.00$540,000.0018,000View SEC Filing  
3/14/2018Barry D QuartCEOSell100,000$24.75$2,475,000.00167,993View SEC Filing  
1/10/2018Kimberly ManhardVPSell7,584$20.00$151,680.007,584View SEC Filing  
4/24/2017Kimberly ManhardVPSell21,542$15.33$330,238.865,250View SEC Filing  
1/19/2017Kevin C TangDirectorBuy2,459,016$12.20$29,999,995.20View SEC Filing  
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00102,640View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00178,968View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Heron Therapeutics (NASDAQ HRTX) News Headlines

Source:
DateHeadline
Heron Therapeutics (HRTX) Overweight Rating Reaffirmed at Cantor FitzgeraldHeron Therapeutics' (HRTX) Overweight Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 20 at 4:17 PM
Heron Therapeutics (HRTX) Upgraded at Zacks Investment ResearchHeron Therapeutics (HRTX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 18 at 11:54 PM
Brokers Issue Forecasts for Heron Therapeutics Q1 2018 Earnings (HRTX)Brokers Issue Forecasts for Heron Therapeutics' Q1 2018 Earnings (HRTX)
www.americanbankingnews.com - April 18 at 7:54 AM
Heron Therapeutics (HRTX) Given Buy Rating at AegisHeron Therapeutics (HRTX) Given Buy Rating at Aegis
www.americanbankingnews.com - April 17 at 5:25 PM
Heron Therapeutics (HRTX) Expected to Announce Quarterly Sales of $10.96 MillionHeron Therapeutics (HRTX) Expected to Announce Quarterly Sales of $10.96 Million
www.americanbankingnews.com - April 15 at 2:30 AM
Zacks: Analysts Expect Heron Therapeutics Inc (HRTX) to Announce -$0.82 Earnings Per ShareZacks: Analysts Expect Heron Therapeutics Inc (HRTX) to Announce -$0.82 Earnings Per Share
www.americanbankingnews.com - April 13 at 7:15 PM
July 20th Options Now Available For Heron Therapeutics (HRTX)July 20th Options Now Available For Heron Therapeutics (HRTX)
www.nasdaq.com - April 13 at 4:51 PM
An Intrinsic Calculation For Heron Therapeutics Inc (NASDAQ:HRTX) Shows It’s 36% UndervaluedAn Intrinsic Calculation For Heron Therapeutics Inc (NASDAQ:HRTX) Shows It’s 36% Undervalued
finance.yahoo.com - April 12 at 9:52 AM
Cantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $40.00 Price TargetCantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $40.00 Price Target
www.americanbankingnews.com - April 7 at 11:26 AM
Pre-Open Movers 04/05: (CHFS) (FNSR) (HRTX) Higher; (CNAT) (CHECK) (CONN) Lower (more...)Pre-Open Movers 04/05: (CHFS) (FNSR) (HRTX) Higher; (CNAT) (CHECK) (CONN) Lower (more...)
www.streetinsider.com - April 5 at 4:49 PM
Evercore ISI Initiates Coverage on Heron Therapeutics (HRTX)Evercore ISI Initiates Coverage on Heron Therapeutics (HRTX)
www.americanbankingnews.com - April 5 at 2:09 PM
Lake Street Capital Analysts Give Heron Therapeutics (HRTX) a $42.00 Price TargetLake Street Capital Analysts Give Heron Therapeutics (HRTX) a $42.00 Price Target
www.americanbankingnews.com - April 5 at 2:08 PM
Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common StockHeron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
finance.yahoo.com - April 5 at 9:32 AM
Cantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $31.00 Price TargetCantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $31.00 Price Target
www.americanbankingnews.com - April 4 at 7:58 PM
Heron Therapeutics Inc (HRTX) Receives Consensus Rating of "Buy" from BrokeragesHeron Therapeutics Inc (HRTX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 5:52 PM
Heron Therapeutics Target of Unusually High Options Trading (HRTX)Heron Therapeutics Target of Unusually High Options Trading (HRTX)
www.americanbankingnews.com - April 4 at 7:58 AM
Financial Contrast: Hutchison China MediTech (HCM) versus Heron Therapeutics (HRTX)Financial Contrast: Hutchison China MediTech (HCM) versus Heron Therapeutics (HRTX)
www.americanbankingnews.com - April 4 at 7:07 AM
Heron Therapeutics (HRTX) Upgraded at ValuEngineHeron Therapeutics (HRTX) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 1:54 PM
Heron Therapeutics Inc (HRTX) Director Buys $5,000,008.00 in StockHeron Therapeutics Inc (HRTX) Director Buys $5,000,008.00 in Stock
www.americanbankingnews.com - April 2 at 4:14 PM
Heron Therapeutics (HRTX) Buy Rating Reaffirmed at Cantor FitzgeraldHeron Therapeutics' (HRTX) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 1 at 11:24 PM
Heron Therapeutics (HRTX) Receives Buy Rating from MizuhoHeron Therapeutics (HRTX) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 1 at 2:38 PM
Heron Is A Solid Long-Term InvestmentHeron Is A Solid Long-Term Investment
seekingalpha.com - March 30 at 4:54 PM
Your Daily Pharma Scoop: Heron Offering, Sorrento Issues Letter To Shareholders, MediciNova SetbackYour Daily Pharma Scoop: Heron Offering, Sorrento Issues Letter To Shareholders, MediciNova Setback
seekingalpha.com - March 30 at 9:04 AM
Zacks Investment Research Downgrades Heron Therapeutics (HRTX) to HoldZacks Investment Research Downgrades Heron Therapeutics (HRTX) to Hold
www.americanbankingnews.com - March 29 at 7:58 PM
Heron Therapeutics down 4% premarket on pricing common stock offeringHeron Therapeutics down 4% premarket on pricing common stock offering
seekingalpha.com - March 29 at 9:20 AM
$10.96 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter$10.96 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter
www.americanbankingnews.com - March 29 at 2:30 AM
Heron Therapeutics Announces Proposed Public Offering of Common StockHeron Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 28 at 4:46 PM
Heron Therapeutics (HRTX) Buy Rating Reaffirmed at MizuhoHeron Therapeutics' (HRTX) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 28 at 12:58 PM
Heron Therapeutics (HRTX) Given a $34.00 Price Target by Oppenheimer AnalystsHeron Therapeutics (HRTX) Given a $34.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - March 28 at 10:58 AM
Heron Therapeutics (HRTX) Buy Rating Reiterated at Northland SecuritiesHeron Therapeutics' (HRTX) Buy Rating Reiterated at Northland Securities
www.americanbankingnews.com - March 26 at 1:24 PM
Heron Therapeutics (HRTX) Lowered to "Hold" at BidaskClubHeron Therapeutics (HRTX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 26 at 8:39 AM
Heron Therapeutics (HRTX) Stock Rating Upgraded by ValuEngineHeron Therapeutics (HRTX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 5:24 PM
Heron Therapeutics (HRTX) Lifted to Buy at BidaskClubHeron Therapeutics (HRTX) Lifted to Buy at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM
Heron Therapeutics (HRTX) Earns Buy Rating from Needham & Company LLCHeron Therapeutics (HRTX) Earns Buy Rating from Needham & Company LLC
www.americanbankingnews.com - March 24 at 2:12 PM
Heron Therapeutics Can Still Rally - Seeking AlphaHeron Therapeutics Can Still Rally - Seeking Alpha
seekingalpha.com - March 24 at 8:21 AM
Heron Therapeutics Inc (HRTX) to Post FY2020 Earnings of $0.75 Per Share, Jefferies Group ForecastsHeron Therapeutics Inc (HRTX) to Post FY2020 Earnings of $0.75 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 22 at 5:18 PM
FY2019 EPS Estimates for Heron Therapeutics Inc (HRTX) Decreased by AnalystFY2019 EPS Estimates for Heron Therapeutics Inc (HRTX) Decreased by Analyst
www.americanbankingnews.com - March 22 at 3:16 PM
Heron Therapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($0.39) Per Share (HRTX)Heron Therapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($0.39) Per Share (HRTX)
www.americanbankingnews.com - March 22 at 9:36 AM
Heron Therapeutics (HRTX) Rating Reiterated by Noble FinancialHeron Therapeutics (HRTX) Rating Reiterated by Noble Financial
www.americanbankingnews.com - March 22 at 8:28 AM
Heron Therapeutics to Present at the 17th Annual Needham Healthcare ConferenceHeron Therapeutics to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 5:10 PM
FY2020 Earnings Forecast for Heron Therapeutics Inc (HRTX) Issued By OppenheimerFY2020 Earnings Forecast for Heron Therapeutics Inc (HRTX) Issued By Oppenheimer
www.americanbankingnews.com - March 21 at 4:02 PM
Your Daily Pharma Scoop: Herons HTX-011, Geron Update, Cidara Tumbles - Seeking AlphaYour Daily Pharma Scoop: Heron's HTX-011, Geron Update, Cidara Tumbles - Seeking Alpha
seekingalpha.com - March 20 at 4:59 PM
UPDATE: Heron Therapeutics stock jumps 28% on news of positive results for anesthetic agent - MarketWatchUPDATE: Heron Therapeutics stock jumps 28% on news of positive results for anesthetic agent - MarketWatch
www.marketwatch.com - March 20 at 4:59 PM
Why Heron Therapeutics Stock Soared TodayWhy Heron Therapeutics Stock Soared Today
finance.yahoo.com - March 20 at 8:59 AM
Needham & Company LLC Increases Heron Therapeutics (HRTX) Price Target to $42.00Needham & Company LLC Increases Heron Therapeutics (HRTX) Price Target to $42.00
www.americanbankingnews.com - March 20 at 8:42 AM
Insider Selling: Heron Therapeutics Inc (HRTX) VP Sells 18,000 Shares of StockInsider Selling: Heron Therapeutics Inc (HRTX) VP Sells 18,000 Shares of Stock
www.americanbankingnews.com - March 19 at 10:10 PM
Insider Selling: Heron Therapeutics Inc (HRTX) CEO Sells 100,000 Shares of StockInsider Selling: Heron Therapeutics Inc (HRTX) CEO Sells 100,000 Shares of Stock
www.americanbankingnews.com - March 19 at 10:10 PM
Heron Therapeutics (HRTX) Earns Buy Rating from CowenHeron Therapeutics (HRTX) Earns Buy Rating from Cowen
www.americanbankingnews.com - March 19 at 9:31 PM
Heron Therapeutics (HRTX) Lowered to "Sell" at ValuEngineHeron Therapeutics (HRTX) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - March 19 at 9:30 PM
Heron Therapeutics (HRTX) Price Target Increased to $35.00 by Analysts at MizuhoHeron Therapeutics (HRTX) Price Target Increased to $35.00 by Analysts at Mizuho
www.americanbankingnews.com - March 19 at 4:31 PM

SEC Filings

Heron Therapeutics (NASDAQ:HRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Heron Therapeutics (NASDAQ:HRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Heron Therapeutics (NASDAQ HRTX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.